Financial Performance: BillionToOne Inc. reported a net income of $1.5 million for Q3 2025, a significant turnaround from a net loss of $14.9 million in the same quarter of 2024, with total revenue rising 117% to $83.5 million.
Product Offerings: The company’s core product, UNITY, is a non-invasive prenatal test, while its oncology products include Northstar Select and Northstar Response, which enhance cancer treatment monitoring and therapy selection.
Growth Metrics: The number of tests delivered increased by 52% to 165,000, and gross profit rose to $58.4 million, with a gross margin improvement to 70% due to higher average selling prices and lower costs.
Future Outlook: BillionToOne anticipates Q4 2025 revenue between $84 million and $90 million, projecting full-year revenue growth of 93% to 96% compared to 2024, following a successful IPO that raised approximately $286.4 million in net proceeds.
Wall Street analysts forecast BLLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLLN is 137.83 USD with a low forecast of 110.00 USD and a high forecast of 160.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast BLLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLLN is 137.83 USD with a low forecast of 110.00 USD and a high forecast of 160.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 94.720
Low
110.00
Averages
137.83
High
160.00
Current: 94.720
Low
110.00
Averages
137.83
High
160.00
No data
About BLLN
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to create molecular diagnostics. The Company's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. It applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
